NCT03912831 - Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2019

Primary Completion Date

February 18, 2022

Study Completion Date

February 18, 2022

Conditions

Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer

Interventions

DRUG

KITE-439

A single infusion of E7 TCR T cells (KITE-439).

DRUG

Cyclophosphamide

Administered intravenously.

DRUG

Fludarabine

Administered intravenously.

DRUG

Interleukin-2

Administered subcutaneously.

Trial Locations (9)

Memorial Sloan Kettering Cancer Center, New York

H. Lee Moffitt Cancer Center and Research Institute, Tampa

University of Chicago Medical Center, Chicago

The University of Texas MD Anderson Cancer Center, Houston

Banner MD Anderson Cancer Center, Gilbert

Ronald Reagan UCLA Medical Center, Los Angeles

City of Hope, Duarte

Fred Hutchinson Cancer Research Center, Seattle

Dana-Farber Cancer Institute, Boston